115.41
1.47%
+1.60
Dexcom Inc stock is currently priced at $115.41, with a 24-hour trading volume of 564.89K.
It has seen a +1.47% increased in the last 24 hours and a -8.33% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $114.6 pivot point. If it approaches the $115.5 resistance level, significant changes may occur.
Previous Close:
$113.81
Open:
$113.55
24h Volume:
564.89K
Market Cap:
$45.90B
Revenue:
$3.80B
Net Income/Loss:
$639.30M
P/E Ratio:
126.82
EPS:
0.91
Net Cash Flow:
$583.50M
1W Performance:
-0.27%
1M Performance:
-8.33%
6M Performance:
-6.19%
1Y Performance:
-9.11%
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
858-200-0200
Address
6340 Sequence Drive, San Diego, CA
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
Mar-29-23 | Initiated | UBS | Buy |
Jan-26-23 | Initiated | Wolfe Research | Outperform |
Oct-18-22 | Initiated | Barclays | Equal Weight |
Oct-12-22 | Initiated | Jefferies | Buy |
Jul-15-22 | Initiated | Bernstein | Outperform |
Mar-02-22 | Resumed | BofA Securities | Buy |
Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
Jul-21-21 | Resumed | Cowen | Outperform |
May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
May-25-21 | Initiated | Barclays | Overweight |
Apr-15-21 | Initiated | Atlantic Equities | Overweight |
Jan-06-21 | Upgrade | UBS | Neutral → Buy |
Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
May-27-20 | Reiterated | Piper Sandler | Overweight |
May-14-20 | Initiated | Wells Fargo | Equal Weight |
Mar-05-20 | Initiated | Citigroup | Buy |
Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
Oct-23-19 | Initiated | Stifel | Buy |
Nov-28-18 | Initiated | UBS | Neutral |
Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
May-11-18 | Initiated | BofA/Merrill | Buy |
May-03-18 | Reiterated | Canaccord Genuity | Buy |
Apr-04-18 | Initiated | Goldman | Sell |
Apr-04-18 | Initiated | Guggenheim | Neutral |
Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
MarketWatch
Parkman Healthcare Partners LLC Sells 39,903 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
MarketBeat
DexCom Inc. stock rises Wednesday, still underperforms market - MarketWatch
MarketWatch
Pitcairn Co. Sells 16,491 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
MarketBeat
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know - Yahoo Movies UK
Yahoo Movies UK
Dexcom's COO sells shares worth over $85000 - Investing.com India
Investing.com India
Dexcom Inc Stock (DXCM) Financials Data
Dexcom Inc (DXCM) Revenue 2024
DXCM reported a revenue (TTM) of $3.80 billion for the quarter ending March 31, 2024, a +25.78% rise year-over-year.
Dexcom Inc (DXCM) Net Income 2024
DXCM net income (TTM) was $639.30 million for the quarter ending March 31, 2024, a +118.56% increase year-over-year.
Dexcom Inc (DXCM) Cash Flow 2024
DXCM recorded a free cash flow (TTM) of $583.50 million for the quarter ending March 31, 2024, a +40.26% increase year-over-year.
Dexcom Inc (DXCM) Earnings per Share 2024
DXCM earnings per share (TTM) was $1.55 for the quarter ending March 31, 2024, a +121.43% growth year-over-year.
Dexcom Inc Stock (DXCM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Leach Jacob Steven | EVP Chief Operating Officer |
Jun 10 '24 |
Sale |
115.05 |
745 |
85,713 |
265,577 |
Stern Sadie | EVP Chief HR Officer |
Jun 10 '24 |
Sale |
115.05 |
427 |
49,127 |
75,877 |
Brown Michael Jon | EVP Chief Legal Officer |
May 31 '24 |
Sale |
119.24 |
652 |
77,744 |
67,560 |
Dolan Matthew Vincent | EVP Strategy and Corporate Dev |
May 15 '24 |
Sale |
126.58 |
2,423 |
306,703 |
40,075 |
Brown Michael Jon | EVP Chief Legal Officer |
Apr 30 '24 |
Sale |
126.25 |
629 |
79,411 |
68,212 |
Dolan Matthew Vincent | EVP Strategy and Corporate Dev |
Apr 15 '24 |
Sale |
137.81 |
1,990 |
274,242 |
42,377 |
SAYER KEVIN R | President CEO and Chairman |
Apr 08 '24 |
Sale |
138.30 |
49,633 |
6,864,136 |
283,893 |
Brown Michael Jon | EVP Chief Legal Officer |
Mar 28 '24 |
Sale |
140.04 |
2,624 |
367,472 |
68,682 |
Stern Sadie | EVP Chief Human Resources |
Mar 25 '24 |
Sale |
140.00 |
4,137 |
579,180 |
76,304 |
Dolan Matthew Vincent | EVP Strategy & Corp Dev |
Mar 15 '24 |
Sale |
130.21 |
4,203 |
547,259 |
44,367 |
About Dexcom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):